We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Olympus, Sony Postpone Joint Venture Indefinitely

By HospiMedica International staff writers
Posted on 08 Apr 2013
Sony (Tokyo, Japan) and Olympus (Tokyo, Japan) are indefinitely delaying their partnership to develop new endoscopes and other medical devices, due to Chinese regulatory issues.

The joint venture was launched on September 28, 2012, when Sony invested JPY 50 billion (USD 532 million) to become Olympus' biggest shareholder. More...
But delays in implementing the joint venture have cascaded since then, principally due to a prolonged regulatory process in China, and difficulties securing antitrust approval in Eastern Europe. The launch date was postponed to April 2013, but that date has now been postponed indefinitely.

Unnamed sources confirmed to the news agency AFP that the delay was linked to Chinese regulators, at a time when Tokyo and Beijing are embroiled in a tense territorial spat over an island chain in the East China Sea. According to the same sources, regulatory delays involving other Japanese firms have been linked to hold ups from the Chinese watchdogs, including the USD 4.8 billion takeover of Aegis media group by Japanese advertising firm Dentsu (Tokyo, Japan), and a merger between steelmaker JFE Holdings and Japanese heavy machinery firm IHI.

“The examination by the relevant authority is taking longer than expected, but we understand the examination process is currently in its final stage. Olympus and Sony expect to announce establishment of the medical business venture promptly after the establishment date is fixed,” revealed a joint update on the status of the medical business venture.

The alliance is seen as beneficial to both technology giants, who are confronting various financial and public challenges, including Sony's push to expand into new areas to counter video game and TV sales losses, and a decade-long USD 1.7 billion accounting problem at Olympus exposed in October 2011.

Related Links:
Sony
Olympus
Dentsu



Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gas Analyzer
GE SAM
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.